vs

Side-by-side financial comparison of ORRSTOWN FINANCIAL SERVICES INC (ORRF) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

ORRSTOWN FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($64.6M vs $35.5M, roughly 1.8× RECURSION PHARMACEUTICALS, INC.). ORRSTOWN FINANCIAL SERVICES INC runs the higher net margin — 33.8% vs -304.2%, a 338.0% gap on every dollar of revenue. Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 39.3%).

Orrstown Financial Services Inc is a US regional bank holding company headquartered in Shippensburg, Pennsylvania. It offers a full range of retail and commercial banking solutions including deposit accounts, personal and business loans, mortgages, and wealth management services, primarily serving customers across central Pennsylvania and northern Maryland.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ORRF vs RXRX — Head-to-Head

Bigger by revenue
ORRF
ORRF
1.8× larger
ORRF
$64.6M
$35.5M
RXRX
Higher net margin
ORRF
ORRF
338.0% more per $
ORRF
33.8%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
39.3%
ORRF

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ORRF
ORRF
RXRX
RXRX
Revenue
$64.6M
$35.5M
Net Profit
$21.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
33.8%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
19.1%
39.6%
EPS (diluted)
$1.12
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORRF
ORRF
RXRX
RXRX
Q1 26
$64.6M
Q4 25
$64.9M
$35.5M
Q3 25
$64.4M
$5.2M
Q2 25
$62.4M
$19.2M
Q1 25
$60.4M
$14.7M
Q4 24
$61.8M
$4.5M
Q3 24
$64.1M
$26.1M
Q2 24
$33.3M
$14.4M
Net Profit
ORRF
ORRF
RXRX
RXRX
Q1 26
$21.8M
Q4 25
$21.5M
$-108.1M
Q3 25
$21.9M
$-162.3M
Q2 25
$19.4M
$-171.9M
Q1 25
$18.1M
$-202.5M
Q4 24
$13.7M
$-178.9M
Q3 24
$-7.9M
$-95.8M
Q2 24
$7.7M
$-97.5M
Gross Margin
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Operating Margin
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
42.3%
-304.8%
Q3 25
43.0%
-3327.6%
Q2 25
39.6%
-916.8%
Q1 25
37.7%
-1297.9%
Q4 24
27.7%
-4042.4%
Q3 24
-15.4%
-377.1%
Q2 24
29.5%
-697.4%
Net Margin
ORRF
ORRF
RXRX
RXRX
Q1 26
33.8%
Q4 25
33.1%
-304.2%
Q3 25
34.0%
-3135.3%
Q2 25
31.2%
-894.2%
Q1 25
29.9%
-1373.3%
Q4 24
22.1%
-3935.5%
Q3 24
-12.3%
-367.5%
Q2 24
23.3%
-676.6%
EPS (diluted)
ORRF
ORRF
RXRX
RXRX
Q1 26
$1.12
Q4 25
$1.11
$-0.17
Q3 25
$1.13
$-0.36
Q2 25
$1.01
$-0.41
Q1 25
$0.93
$-0.50
Q4 24
$0.35
$-0.56
Q3 24
$-0.41
$-0.34
Q2 24
$0.73
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORRF
ORRF
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$161.8M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$603.2M
$1.1B
Total Assets
$5.6B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORRF
ORRF
RXRX
RXRX
Q1 26
$161.8M
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Total Debt
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Stockholders' Equity
ORRF
ORRF
RXRX
RXRX
Q1 26
$603.2M
Q4 25
$591.5M
$1.1B
Q3 25
$571.9M
$1.0B
Q2 25
$548.4M
$919.1M
Q1 25
$532.9M
$933.9M
Q4 24
$516.7M
$1.0B
Q3 24
$516.2M
$524.6M
Q2 24
$278.4M
$584.4M
Total Assets
ORRF
ORRF
RXRX
RXRX
Q1 26
$5.6B
Q4 25
$5.5B
$1.5B
Q3 25
$5.5B
$1.4B
Q2 25
$5.4B
$1.3B
Q1 25
$5.4B
$1.3B
Q4 24
$5.4B
$1.4B
Q3 24
$5.5B
$726.5M
Q2 24
$3.2B
$775.9M
Debt / Equity
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORRF
ORRF
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
$74.7M
$-46.1M
Q3 25
$22.8M
$-117.4M
Q2 25
$24.5M
$-76.4M
Q1 25
$11.0M
$-132.0M
Q4 24
$35.0M
$-115.4M
Q3 24
$7.5M
$-59.2M
Q2 24
$6.4M
$-82.2M
Free Cash Flow
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
$70.5M
$-47.3M
Q3 25
$22.3M
$-117.6M
Q2 25
$23.7M
$-79.6M
Q1 25
$8.6M
$-133.8M
Q4 24
$33.4M
$-116.7M
Q3 24
$7.1M
$-63.8M
Q2 24
$6.4M
$-83.4M
FCF Margin
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
108.6%
-133.1%
Q3 25
34.7%
-2272.5%
Q2 25
37.9%
-413.9%
Q1 25
14.3%
-907.4%
Q4 24
54.0%
-2567.7%
Q3 24
11.1%
-244.6%
Q2 24
19.2%
-578.5%
Capex Intensity
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
6.5%
3.5%
Q3 25
0.8%
4.7%
Q2 25
1.3%
16.4%
Q1 25
3.8%
12.4%
Q4 24
2.6%
28.6%
Q3 24
0.6%
17.5%
Q2 24
0.1%
8.2%
Cash Conversion
ORRF
ORRF
RXRX
RXRX
Q1 26
Q4 25
3.48×
Q3 25
1.04×
Q2 25
1.26×
Q1 25
0.61×
Q4 24
2.55×
Q3 24
Q2 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ORRF
ORRF

Net Interest Income$49.0M76%
Noninterest Income$15.6M24%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons